SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. “We are thrilled to welcome Dan to NeuraClick,” said Dr. Subhi Marwari , Chief Executive Officer. “For an early-stage venture, experienced guidance is essential, and Dan’s deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. About NeuraClick, Inc.NeuraClick, Inc. is a privately held, preclinical-stage biopharmaceutical company developing novel neurotherapeutics using its proprietary click chemistry technology applied to naturally occurring peptides. The company aims to create safer, more potent drugs that are easy to administer, long-acting, and free from major side effects.